Physician profile
Nathaniel Lebowitz
NPI 1063418994
$92,311.91
in general payments reported to CMS, 2019-2025
43 companies · $15K in 2025
The $15K reported for 2025 was more than what 96% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $11K · 2021: $15K · 2022: $9,301 · 2023: $3,024 · 2024: $10K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $5,186 · Consulting Fee: $3,850 · Travel and Lodging: $977 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,668.00 |
| Food and Beverage | $5,186.35 |
| Consulting Fee | $3,850.00 |
| Travel and Lodging | $977.39 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $41,716.14 | 2019-2025 | Repatha, Repatha |
| Amarin Pharma, INC. | $25,705.16 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $8,092.73 | 2019 | |
| Medicure Pharma INC. | $6,760.84 | 2019-2025 | Zypitamag |
| Boston Scientific Corporation | $3,631.47 | 2019-2025 | Watchman Access System, Watchman Flx, Watchman |
| Novartis Pharmaceuticals Corporation | $1,571.40 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,167.32 | 2019-2023 | Evkeeza |
| Kowa Pharmaceuticals America, INC. | $436.95 | 2019-2022 | |
| Cvrx, INC. | $373.50 | 2022-2024 | Barostim Neo System |
| Novo Nordisk INC | $340.06 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $278.86 | 2022-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $224.43 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $221.61 | 2019-2025 | Eliquis, Camzyos |
| Esperion Therapeutics, INC. | $191.00 | 2021-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $178.65 | 2019 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Lebowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.